 |
|
|
INCC .55 Shares Outstanding 12.03 M Float: 10.03 M 1/28/2008 |
| International Consolidated Companies, Inc. specializes in acquiring international businesses located in the expanding Asian markets focusing on three dynamic areas: healthcare, technology and environment. Utilizing a unique acquisition model International Consolidated Companies, Inc. provides foreign companies an opportunity to gain access to U.S. capital markets. In exchange, International Consolidated Companies, Inc. retains a significant percentage of each target company, creating a diversified, growth oriented investment base that should enjoy a steady, long-term increase. Each target company reviewed for acquisition must meet specific criteria detailed in International Consolidated Companies, Inc.'s acquisition model and has proven commercial track records. |
| The company has executed a Letter of Intent (LOI) to acquire Hebei Jiasheng Pharmaceutical & Chemical Limited Co. and its subsidiaries located in Shijiazhuang City, Hebei Province Peoples Republic of China. The company and its subsidiaries have 21 plus years experience and a strong management team. With 1,000 employees the company is well organized with a diversified balance across research, sales and manufacturing. They manufacture and sell biopharmaceutical compounds to the United States and European markets and have established markets in many key foreign countries for their products. With a good understanding of their markets, the company has a clear corporate vision of where they want to go with their new and existing products. Their knowledge of the marketplace and regulatory compliant operation combined with their sales and marketing expertise gives the company a clear competitive edge. They have a Regulatory & Quality Assurance Department that is capable of obtaining regulatory clearance in the US and Internationally. Their products are GMP (Good Manufacturing Practice) certified and compliant with the pharmacopoeia of many countries. 2006 UNAUDITED REVENUE of USD $30 million and after tax profits of USD $ 3 million. 2007 UNAUDITED REVENUE of USD $40 million and after tax profits of USD $ 4 million. The UNAUDITED BALANCE SHEET has USD $50 million in assets. The Terms of the Acquisition will be announced following completion of due diligence and audit and the Definitive Acquisition Agreement is executed. With this addition to the International Consolidated Companies, Inc. family, the Company is rapidly gaining the reputation in China for attracting well managed, highly respected quality Companies. On January 16th International Consolidated Companies, Inc.announced that it finalized the Definitive Acquisition Agreement to acquire 100% of China Gene, Ltd. (Hong Kong). The company welcomes the opportunity to work with China Gene, Ltd. and embraces the chance to aid in the capital growth of this exciting Company. ICC will realize the future revenues and current assets associated with the acquisition without additional management expenses or costs. As of June 30, 2007 China Gene, Ltd. had consolidated total assets of $13.1 million, consolidated total sales of $3.1 million, consolidated total liabilities of $7.2 million, consolidated gross profit of $1.7 million and consolidated net income of $800,000 as reported by the Company's auditors, Bagell, Josephs, Levine & Company, LLC. The China Report names INCC a top five pick for 2008 http://chinareport2008.com |
| The Market |
|
The initial market that INCC has entered is bio-tech pharmaceuticals and bioengineered medicines. China’s pharmaceutical sector has maintained steady growth over the past few years with revenues moving to $54.6 billion, up nearly 26% last year. The pace of growth in China bio-pharma seems to be picking up, as the industry lives up to the often used term “China Speed.” Perhaps the report with the most far-reaching significance was a story about the as-yet unannounced 11 billion RMB ($1.5 billion) initiative of China’s government to stimulate a native innovative drug sector. According to the latest rumors, the program will be formally announced in March. “China Speed” is the term used to describe the sometimes near-miraculous velocity at which things get done in China… |
| Contact |
| International Consolidated Companies, Inc 2100 19th Street Sarasota, FL 34234 Phone: 941-330-0336 Fax: 941-330-0252 E-mail: info@iccina.com Web Site: http://www.signmediasystems.com |